Heart Failure — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for heart failure. 24 active patents protecting 2 drugs from 2+ originators. First major cliff: 2031. Daily refresh.

2
Approved drugs
24
Active US patents
55/100
Avg vulnerability
—
Annual revenue covered

Originators in Heart Failure

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Merck & Co. 18 patents Lexicon Pharms Inc 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating heart failure. Each bar = one year. Y-axis scaled to peak year (15 patents).

4
28
2
30
15
31
3
32

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Verquvo
VERICIGUAT
 Merck & Co. 18 49 — 2031-05-19
Inpefa
SOTAGLIFLOZIN
 Lexicon Pharms Inc 6 61 — 2028-05-04

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7781577 Inpefa method of use 83 2028-05-04
7781577 Inpefa method of use 83 2028-05-04
8476413 Inpefa method of use 83 2028-05-29
8476413 Inpefa method of use 83 2028-05-29
11439642 Verquvo method of use 76 2031-05-19
11439642 Verquvo method of use 76 2031-05-19
11439642 Verquvo method of use 76 2031-05-19
9993476 Verquvo method of use 68 2031-05-19
8921377 Verquvo method of use 68 2031-05-19
8921377 Verquvo method of use 68 2031-05-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10736896 Verquvo composition of matter 10 2031-05-19
10736896 Verquvo composition of matter 10 2031-05-19
8420656 Verquvo composition of matter 10 2031-05-19
8420656 Verquvo composition of matter 10 2031-05-19
10736896 Verquvo composition of matter 10 2031-05-19
8420656 Verquvo composition of matter 10 2031-05-19
8217156 Inpefa composition of matter 18 2030-10-07
8217156 Inpefa composition of matter 18 2030-10-07
9604948 Verquvo method of use 62 2032-11-26
9604948 Verquvo method of use 62 2032-11-26

Related